Lidocaine for Oxaliplatin-induced Neuropathy

Inclusion Criteria: * Stage III and IV colorectal cancer. * Scheduled for oxaliplatin treatment in mFOLFOX6-based chemotherapy regimen. * Able to understand and willing to sign an IRB-approved written informed consent document. Exclusion Criteria: * Renal insufficiency (defined as calculated Creatinine clearance \< 30mL/min) * Moderate to severe liver failure (defined as ALT or AST \> 3 times upper limit of normal if no liver metastases are present; ALT or AST \> 5 times upper limit of normal if liver metastases are present). * Presence of brain metastases. * Patients with currently uncontrolled cardiac arrhythmias (non-sinus rhythm). * Patients with history of arrhythmias under pharmacological/pacemaker control will be allowed, except if receiving antiarrhythmic medication listed in "contra-indicated medications". * Contraindication or allergy to intravenous lidocaine. * Pre-existing symmetric peripheral painful neuropathy. * Treated with chemotherapy within the past 12 months. * Pregnancy or breastfeeding * Currently treated with any of the following contraindicated medications: Saquinavir, Lopinavir, Amprenavir, Atazanavir, Delavirdine, Mexiletine (and other types of sodium-channel blocker antiarrhythmics), Phenytoin, Carbamazepine, Oxcarbazepine, Lamotrigine, Amiodarone, Dronedarone, Dihydroergotamine, Cimetidine